Effect of omega-3 LCPUFA supplementation on maternal fatty acid and oxylipin concentrations during pregnancy

K P Best^{1,2}, R A Gibson^{1,3}, L N Yelland^{1,4}, S Leemaqz¹, J Gomersall^{1,4}, G Liu¹, M Makrides^{1,2}

Authors' affiliations:

¹South Australian Health and Medical Research Institute, SAHMRI Women and Kids, North Terrace, Adelaide SA

²School of Medicine, University of Adelaide, North Terrace, Adelaide SA

³School of Agriculture, Food and Wine, University of Adelaide, North Terrace, Adelaide SA

⁴School of Public Health, University of Adelaide, North Terrace, Adelaide SA

Corresponding author:

Dr Karen Best

SAHMRI Women and Kids Theme

South Australian Health and Medical Research Institute (SAHMRI)

Women's and Children's Hospital, Level 7, 72 King William Road, North Adelaide, South Australia 5006

T: +61 8 8128 4416

E: karen.best@sahmri.com

Keywords: Omega-3 fatty acids, docosahexaenoic acid, oxylipins, polyunsaturated fatty acids, pregnancy.

Abbreviations used: AA, arachidonic acid; ALA, alpha linolenic acid; DBS, dried blood spot; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid, EPA, eicosapentaenoic acid; FAME, fatty acid methyl esters; LA, linolenic acid; LC-MS-MS, Liquid Chromatography with tandem mass spectrometry; LCPUFA, long chain polyunsaturated fatty acid; ORIP, Omega-3 fats to Reduce the Incidence of Prematurity; PUFA, polyunsaturated fatty acids.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ABSTRACT

Introduction: Omega-3 long chain polyunsaturated fatty acids (LCPUFA) have been associated with a reduction in risk for preterm birth. However, there is limited understanding of how fatty acids and their bioactive derivatives (oxylipins) change over the course of pregnancy. Here we document the changes in concentration of fatty acids and oxylipins during pregnancy and how fatty acid status and oxylipin concentrations are affected by supplementation with omega-3 LCPUFA. We also investigate the degree to which fatty acid and oxylipin changes across pregnancy are influenced by baseline omega-3 status.

Materials and Methods: We profiled the fatty acids in all lipids in dried blood spots (total blood fatty acids) by gas chromatography and free (unesterified) fatty acids and their associated oxylipins in separate dried blood spot samples by LC-MS-MS collected from a random sample of 1263 women with a singleton pregnancy who participated in the ORIP (Omega-3 fats to Reduce the Incidence of Prematurity) trial. ORIP is a double-blind, randomized controlled trial involving 5544 participants and designed to determine the effect of supplementing the diets of pregnant women with omega-3 LCPUFA on the incidence of early preterm birth. Maternal whole blood finger prick samples were collected at baseline (~14 weeks gestation) and at completion of the study intervention period (34 weeks gestation).

Results: The concentration of most total and free polyunsaturated fatty acids and their associated oxylipins declined over the course of pregnancy. Omega-3 LCPUFA supplementation increased total DHA and 7-HDHA and mitigated the decline in free DHA, 4-HDHA and 14-HDHA. The intervention had minimal or no effect on free EPA, LA, AA and their associated oxylipins. Omega-3 LCPUFA supplementation in women with higher omega-3 status at baseline was associated with a significant increase in 7-HDHA and 4-HDHA between the treatment and control whereas there were no differences between groups in 7-HDHA and 4-HDHA in women with intermediate or lower baseline omega-3 status.

Conclusion: Our data suggest a differential response with or without omega-3 supplementation for DHA and DHA-derived oxylipins, which may have an important role to play in modulating pregnancy duration. Further work is needed to understand their role, which may allow us to better tailor omega-3 supplementation for preterm birth prevention.

1. Introduction

There is strong evidence to support maternal supplementation with omega-3 long chain polyunsaturated fatty acids (LCPUFAs) to reduce the risk of preterm birth [1, 2]. Some of the pro- or anti-inflammatory effects of LCPUFAs can be attributed to their oxidized products, collectively known as oxylipins. Oxylipins comprise a large, heterogeneous family of bioactive mediators that have essential roles in normal physiology and function [3]. Synthesis usually occurs via the cyclooxygenase, lipoxygenase or cytochrome P450 pathways [4] and alterations in oxylipin concentrations have been described for numerous diseases in human and animal models [5-9].

During pregnancy, oxylipins are known to alter the function of the placenta, vascular and immune responses [9-11], yet little is known about how total and free fatty acid and oxylipin levels change during pregnancy. Our recent secondary analysis of singleton pregnancies in the ‘Omega-3 fats to Reduce the Incidence of Prematurity’ (ORIP) trial, suggests that the sum of all omega-3 fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA] + docosapentaenoic acid [DPA] + alpha linolenic acid [ALA]) in whole blood lipids in early pregnancy, is the strongest biomarker to predict early preterm birth. We found that women with a low omega-3 baseline status ($\leq 4.1\%$ of total fatty acids) are at higher risk of early preterm birth (< 34 weeks gestation) and that this risk can be reduced by omega-3 LCPUFA supplementation. However, the data also suggest that supplementing mothers who are already replete in omega-3 ($> 4.9\%$ total fatty acids) with additional omega-3 LCPUFA, significantly increases the risk of early preterm birth [12]. Because of the high biological activity of LCPUFAs and their derived oxylipins [13-15], we sought to determine whether omega-3 LCPUFA supplementation leads to oxylipin changes that may be critical to prevent preterm birth.

Using maternal fatty acid status data from blood collected from singleton pregnancies at entry to our ORIP trial (~ 14 weeks’ gestation), we explored the changes in concentration of whole blood lipid fatty acids, free fatty acids and oxylipins during pregnancy from around 14 to 34 weeks’ gestation. Here we describe differences between women who were supplemented with omega-3 LCPUFA and non-supplemented women in the control group. Because the ORIP Trial intervention contained 90% DHA and 10% EPA, our analyses focused on these omega-3 LCPUFA. Since it is possible that some

interconversion of omega 3 fatty acids occurred, we examined changes in whole blood lipid omega-3 status (sum of all omega-3 fatty acids; DHA, EPA, DPA and ALA) and free omega-3 fatty acids. Key competitive omega-6 fatty acids, arachidonic acid (AA) and linolenic acid (LA) were also examined. In particular, to explore differential effects of omega-3 LCPUFA supplementation in pregnancy [12], we also report the degree to which the baseline omega-3 status altered the changes in the concentration of free fatty acids and oxylipins over time with treatment.

2. Participants and Methods

2.1. ORIP Trial - Sample Collection

The ORIP trial was a multicenter, double-blind, randomized controlled trial designed to determine the effect of supplementing the diets of pregnant women with omega-3 LCPUFA on the incidence of early preterm birth [16, 17]. The ORIP trial primary results have been previously published [17]. Women were recruited to the ORIP trial prior to 20 weeks' gestation, with few exclusions, including those who had been regularly consuming a low dose DHA supplement (≤ 150 mg per day) and were willing to cease. A total of 5544 women were randomized to receive either ≈ 900 mg omega-3 LCPUFA (3 x DHA enriched fish oil/day (≈ 800 mg DHA and ≈ 100 mg eicosapentaenoic acid (EPA)/day)) or isocaloric vegetable oil control capsules with trace fish oil for masking (≈ 15 mg DHA and ≈ 4 mg EPA/day) until 34 weeks of gestation. A finger prick blood sample was collected from participants on to chemically treated filter paper as two dried blood spots [18] at baseline (~ 14 weeks') and 34 weeks' gestation [17]. A simple random sample of 1382 ORIP women were selected for further detailed analyses.

The present study reports findings from additional analyses of dried blood spot samples to measure concentration of fatty acids and their associated oxylipins among women in this random sample who had a singleton pregnancy. Measures in maternal capillary whole blood, collected at ~ 14 and 34 weeks' gestation, are reported in **Supplementary Table 1**.

2.2. Laboratory Analysis

All fatty acid analyses were undertaken in the fatty acid laboratory at the School of Agriculture and Wine, University of Adelaide. Briefly, the dried blood spot on a chemically treated paper (18) was treated as follows:

For total fatty acids (the complete fatty acid spectrum from all lipids in blood), the first blood spot was placed in a 6mL vial (Wheaton, Millville, USA) with 2 mL of 1% (v/v) H₂SO₄ (18M, AR grade, BDH, Sussex, UK) in anhydrous methanol (Merck, Darmstadt, Germany), sealed and heated at 70°C for 3 hours. The resultant fatty acid methyl esters (FAME) were extracted into heptane (Merck, Darmstadt, Germany). FAME were separated and quantified using an Agilent 7890 Gas Chromatograph (Agilent, CA, USA) equipped with a BPX70 capillary column 30 m x 0.25 mm, film thickness 0.25 µm (Trajan Pty Ltd., Victoria, Australia), programmed temperature vaporization injector (at 250°C) and a flame ionization detector (at 300°C). A programmed temperature ramp (140-240°C) was used. Helium gas was utilized as a carrier at a flow rate of 1 mL/min in the column and the inlet split ratio was set at 20:1. The FAME were identified and quantified by comparing the retention times and peak area values of unknown samples to those of commercial lipid standards (Nu-Chek Prep Inc., Elysian, MN, USA) using the Agilent Chemstation data system.

For free fatty acids (non-esterified fatty acids) and their oxylipins, a 6 mm disc of blood was obtained from the second dried blood spot and placed into a separated well in a 96-well plate with extraction solvent (150 µL of 80% aqueous methanol) containing deuterated internal standards (d₅-DHA, d₈-AA, d₅-EPA, d₄-LA, d₈-12S-HETE, d₄-LTB₄ and d₄-13S-HODE). The plate was covered and gently shaken on a plate shaker for 30 min at room temperature, and the extract was analyzed using an Agilent 1290 infinity ultra-high-performance liquid chromatography equipped with AB SCIEX 5500 triple quadrupole tandem mass spectrometer, using electrospray ionisation in negative mode. The mass spectrometer had the following conditions: nitrogen was used as the source gas; curtain gas and collision gas were set at 20 and 6 arbitrary units, respectively; capillary voltage was -4500 V; entrance potential was set at -10 V and temperature was set at 200 °C [19, 20].

2.3. Statistical Analysis

A separate analysis was performed for each fatty acid and oxylipin. The analysis was performed on the available data and any values below the limit of detection were set to half the limit of detection. The data were analyzed using a linear model including treatment group, time point and their interaction, with adjustment for the randomization strata (enrolment center and recent omega-3 supplementation). Clustering due to repeated measurements over time was taken into account using generalized estimating equations with an exchangeable working correlation structure. Post hoc comparisons were performed to test whether there were changes in the concentration of the fatty acids and oxylipins over time (34 weeks' vs baseline) separately within each group, and whether there were differences between the groups in the changes in concentration over time (omega-3 change over time vs control change over time). Statistical significance was assessed at the $P < 0.05$ level and 95% confidence intervals were calculated for all estimated effects, without adjustment for multiple comparisons.

A sensitivity analysis was performed using multilevel tobit regression models, where values below the limit of detection were treated as censored. The multilevel tobit regression approach was chosen to be a sensitivity analysis, rather than the primary analysis, due to the small number of oxylipins affected, the generally small percentage of values below the limit of detection, and concerns over the constant variance assumption required for the multilevel tobit regression model.

Exploratory analyses were performed for DHA and total omega-3 fatty acids to investigate whether the changes in the concentration of fatty acids and oxylipins over time within each treatment group and the differences between treatment groups depended on baseline omega-3 status. Women were categorized as having low ($\leq 4.1\%$), moderate (> 4.1 to $\leq 4.9\%$) or high ($> 4.9\%$) baseline omega-3 status, corresponding to subgroups where omega-3 LCPUFA supplementation has been shown to significantly reduce the risk, have no significant effect, or significantly increase the risk of early preterm birth, respectively [12]. The analysis model included treatment group, time point, baseline omega-3 status category and all 2 and 3-way interactions. Post hoc comparisons were performed to

test for differences between the high and low status categories ($>4.9\%$ vs $\leq 4.1\%$) in the change over time within groups and the difference between groups in these changes over time. All analyses were performed using R version 3.6.2.

3. Results

3.1. Characteristics of the study population

Of the 5544 women enrolled in the ORIP Trial, 1382 women were randomly selected to have their blood samples undergo further analysis to determine fatty acid and oxylipin concentrations. This report presents findings for the 1263 women in this random sample who had a singleton pregnancy and baseline dried blood spot data, of which 1023 (81%) also had a dried blood spot sample at 34 weeks' gestation, **Figure 1**. Descriptive analyses showed that women in both groups had comparable baseline characteristics and fatty acid profiles as expected due to randomization, **Table 1**. Oxylipins at baseline were also similar by group, as shown in **Supplementary Table 2**.

3.2. Changes in concentration of fatty acids and oxylipins over time and between groups

The concentration of most fatty acids and oxylipins changed significantly over pregnancy in both the omega-3 LCPUFA and control groups. While the concentration of most fatty acids and oxylipins decreased with gestational age, some increases were observed.

Omega-3 Fatty Acid Results

3.2.1. DHA

Total DHA decreased during pregnancy in the control group. This was more than offset by supplementation with omega-3 LCPUFA. In contrast, free DHA decreased over pregnancy in both groups, but the drop was significantly smaller in the omega-3 LCPUFA group. This pattern seen for free DHA was mirrored for oxylipins 4-HDHA and 14-HDHA, while 7-HDHA followed the same pattern as total DHA. Omega-3 intervention had no significant effect on the change over pregnancy in 19,20 EpDPA, **Figure 2**.

3.2.2. EPA

Total EPA decreased significantly over the course of pregnancy, and this was largely ablated by the omega-3 LCPUFA intervention. The changes in free EPA during pregnancy largely reflected those seen in the total EPA with the omega-3 intervention maintaining baseline levels. There was no effect of omega-3 LCPUFA supplementation on the EPA derived oxylipin 18-HEPE, with both groups showing a significant decline over pregnancy **Figure 3**.

3.2.3. Omega-3 Fatty Acids Status

The sum of the omega-3 fatty acids in the lipids in dried blood spot (ALA, EPA, DPA and DHA) decreased in the control group from baseline to 34 weeks but increased in the omega-3 LCPUFA supplemented group. The aggregate of free omega-3 fatty acids declined with gestational age in both groups, though the decline was larger in the control group **Figure 6**.

Omega-6 Fatty Acid Results

3.2.4. AA

Both total blood lipid AA and free AA declined between baseline and 34 weeks' gestation, with a larger decline seen in the omega-3 LCPUFA group. While AA oxylipin derivatives significantly rose or fell over pregnancy, no differences were observed between the groups **Figure 4**.

3.2.5. LA

There was a small but significant reduction in total blood lipid LA in the control group over the course of pregnancy which was negated by omega-3 LCPUFA treatment. In contrast, free LA increased with gestational age in both groups. However, all LA derived oxylipins decreased over pregnancy independently of the treatment groups **Figure 5**.

Further details, including estimated effects and 95% confidence intervals, can be found in **Supplementary Table 3**. Similar results were obtained in the sensitivity analysis (data not shown).

3.2.6. *Effect of baseline omega-3 status on DHA and associated oxylipins*

We previously reported that the effects of omega-3 LCPUFA supplementation on early preterm birth could be categorized by omega-3 status at baseline (early pregnancy ~14 weeks gestation) [12]. For the random cohort reported here, there were 195 (15.4%) women with a baseline omega-3 status of $\leq 4.1\%$ (low baseline status); 518 (41.0%) >4.1 to $\leq 4.9\%$ (moderate baseline status), and 550 women (43.5%) $>4.9\%$ (high baseline omega-3 status). Baseline omega-3 status significantly influenced the effects of omega-3 LCPUFA supplementation on changes over pregnancy for 7-HDHA and the aggregate of free omega-3 fatty acids (interaction $P < 0.05$), **Table 2**. 7-HDHA showed a decline over pregnancy across the three categories of baseline omega-3 status within the control group. Omega-3 LCPUFA supplementation resulted in no significant change in 7-HDHA over the course of pregnancy for categories $\leq 4.1\%$ and >4.1 to $\leq 4.9\%$, but an increase in women with high baseline status $>4.9\%$, leading to a significant difference between the groups in this baseline category. A similar pattern was also observed for 4-HDHA (interaction $P < 0.06$). Free omega-3 decreased over time in both groups across all three categories of baseline omega-3 status. However, omega-3 LCPUFA supplementation resulted in significantly smaller decreases over time among women with moderate or high omega-3 baseline status, **Table 2**. Additional post hoc comparisons testing for differences between women with high and low baseline status ($>4.9\%$ vs $\leq 4.1\%$) showed that differences in the change over pregnancy between the groups were significantly larger among women with high compared to low baseline status for free DHA, 4-HDHA, 7-HDHA and the sum of free omega-3 fatty acids, **Supplementary Table 4** and **Supplementary Figures 1 to 4**.

4. Discussion and Conclusions

We anticipated that omega-3 LCPUFA supplementation would mostly affect DHA and DHA-derived oxylipins rather than EPA and EPA-derived oxylipins, because of the small dose of EPA included in the study intervention. We also assumed that supplementation of women with an oil blend rich in DHA would increase the levels of DHA and its metabolites in dried blood spots. Thus, the increased total blood lipid DHA, 7-HDHA, and 19,20 EpDPA due to supplementation seemed logical. We had

not anticipated the fact that several of the oxygenated metabolites of DHA naturally declined over the assessed 20-week period of gestation. However, omega-3 LCPUFA supplementation reduced the declines of free DHA, 4-HDHA, and 14-HDHA between the end of the first trimester of pregnancy and 34 weeks of gestation so that overall the effect of supplementation was consistent in that there was an overall increase in DHA and its various metabolites relative to no supplementation.

Although early preterm births would have occurred between the two sampling periods in our study (14 and 34 weeks of gestation) we nevertheless considered it important to understand these biochemical data in the context of the clinical outcomes from the ORIP trial. Interestingly, secondary analyses of the ORIP Trial showed that the benefit of omega-3 LCPUFA supplementation on reducing the risk of early preterm birth was limited to women with low baseline omega-3 status ($\leq 4.1\%$); women who already had a higher baseline status of omega-3 fatty acids ($> 4.9\%$) and who were supplemented with additional DHA, increased their risk of early preterm birth [12]. Thus, it is pertinent to explore the relationships between changes in oxylipins recorded here according to these measures of omega-3 status. In particular, whether the changes in oxylipins in relation to baseline measures and effects of omega-3 LCPUFA supplementation could explain the apparently contradictory effects of supplementation on clinical outcomes. Namely, why omega-3 LCPUFA supplementation lowered the risk of early preterm birth in women with low omega-3 status at baseline, while the same treatment increased the risk of early preterm birth in women with high omega-3 status at baseline. Our data demonstrated that it was the 5-lipoxygenase derivatives, 7-HDHA and 4-HDHA, whose response to omega-3 LCPUFA supplementation was influenced by the baseline omega-3 status. Omega-3 LCPUFA supplementation in women with higher omega-3 status at baseline was associated with a significant increase in 7-HDHA and 4-HDHA between treatment and control whereas there were no differences between groups in 7-HDHA and 4-HDHA in women with moderate or low omega-3 status. It is therefore feasible that the increase in the 5-lipoxygenase derivatives associated with DHA supplementation in women with already high omega-3 fatty acid status may be causally related to the increased risk of early preterm birth in these women. However, there was no evidence of 7-HDHA and 4-HDHA being affected by omega-3 LCPUFA

supplementation in women with low omega-3 status, where risk of early preterm birth was high, and supplementation effectively lowered this risk. Further exploration is needed to understand the role of 5-lipoxygenase products as well as other oxylipins in determining the timing of birth at both high and low baseline omega-3 status.

The changes seen in the current report were consistent with a much smaller study also nested within the ORIP trial that involved plasma samples (rather than whole blood from dried blood spots) collected at trial entry (end of the first trimester) and 24 weeks of gestation, indicating that the observed changes happen relatively quickly [21]. The clinical significance of these changes is yet to be fully determined, although this earlier study [21] did hypothesize that higher 5-lipoxygenase derivatives of both DHA and AA in early to mid-pregnancy were associated with increased risk of spontaneous preterm birth.

Traditionally, the timing of parturition has been discussed in terms of cyclooxygenase products, largely involving a preponderance of the AA derivatives PGE₂ and PGF₂ α , with the equivalent derivatives from EPA being significantly less potent [9, 22, 23]. Our technology was not sensitive enough to accurately detect these cyclooxygenase products in the collected dried blood spots, although the pattern of change of a related prostaglandin (PGD₂) across pregnancy did not differ between the omega-3 LCPUFA and control groups.

Surprisingly, our data showed very little, if any, difference in the pattern of change of total lipid and free omega-6 AA and LA between omega-3 supplemented and control groups, and this lack of difference also resulted in no differences between groups in their measured oxylipin derivatives. In non-pregnant adults and lactating women, the equivalent omega-3 LCPUFA supplementation with 800mg DHA would be expected to reduce blood AA levels by more than the small reduction observed in this study [24]. It may be that the hormonal and hemodynamic changes that occur over the course of pregnancy are partially designed to maintain an AA-associated homeostasis. Interestingly, from the oxylipins assessed it was only three AA derived oxylipins, which are 5-lipoxygenase products (5-

262 HETE, LXA4, LXB4), that naturally increased over the course of pregnancy regardless of omega-3
263 supplementation. .

264 Our study had several strengths. It was nested in a randomized controlled trial, had large numbers and
265 matched fatty acids in total blood lipids with the free fatty acid pool and their derived oxylipins,
266 providing us with some important insights into how fatty acids and oxylipins change over the course
267 of pregnancy, and how this trajectory is influenced by omega-3 LCPUFA supplementation. A study
268 such as this would have been more difficult logistically and more costly without the use of the dried
269 blood spot technology, although we were not able to consistently detect the cyclooxygenase products.
270 The main limitation is that we were not able to reliably link the fatty acid and oxylipin changes
271 between 14 and 34 weeks of gestation directly with prematurity, as we would have missed all the
272 preterm births occurring before 34 weeks of gestation.

273 In summary, this is a large and comprehensive study to document fatty acid and oxylipin changes
274 across pregnancy. We demonstrated that most fatty acids in both total blood lipid and free fatty acid
275 fractions and their associated oxylipins decline over the course of pregnancy, with a few notable
276 exceptions related to 5-lipoxygenase products. Omega-3 LCPUFA supplementation mostly arrested
277 the declines in free DHA and DHA-derived oxylipins, with a suggestion of a differential response in
278 the 5-lipoxygenase products depending on the baseline omega-3 status of women. Our work has
279 added to the speculation that 5-lipoxygenase products have an important role to play in modulating
280 pregnancy duration. Further work to understand their role will allow us to better tailor treatments for
281 women to achieve optimal pregnancy outcomes.

282 Acknowledgements

283 We thank the women and their families for their participation in the original study.

284 Disclosure of Interests:

- 285 • Dr. Gibson received supplies from Croda UK, prepared supplies for the ORIP trial for
- 286 Efamol/Wassen UK.
- 287 • Dr Gibson and Dr Liu hold a patent (WO2013/10 40 25 A1) on stabilizing and analyzing fatty
- 288 acids in a biologic sample stored on solid media, owned by Adelaide Research and Innovation,
- 289 the University of Adelaide, and licensed to Xerion.
- 290 • Dr. Makrides received supplies from Croda UK, and prepared supplies for the ORIP trial for
- 291 Efamol/Wassen UK.
- 292 • Dr. Best, Dr Yelland, Dr Leemaqz and Dr. Gomersall have no conflicts of interest to disclose.

293 **Contribution to Authorship:** RAG and MM, conceived the analysis. KPB, RAG, LNY, JG and MM
 294 were involved in the analysis and interpretation of data and SL and LNY carried out the statistical
 295 analyses. KB drafted the manuscript and all authors critically revised and edited the manuscript and
 296 approved the final submitted version. All authors take responsibility for the integrity of the data and
 297 the accuracy of the data analysis.

298 **Funding:** The original study was supported by grants from the National Health and Medical Research
 299 Council (NHMRC) (1050468) and the Thyne Reid Foundation, and fellowships awarded to M
 300 Makrides (1061704), RA Gibson (1046207) and LN Yelland (1052388) from the NHMRC. The
 301 secondary analysis was supported by the National Health and Medical Research Council Centre of
 302 Research Excellence in Targeted Nutrition to Improve Maternal and Child Health Outcomes
 303 (1135155). KP Best was supported by a Women's and Children's Hospital Foundation, MS McLeod
 304 Fellowship.

Figure 1. Flowchart of participants in the ORIP trial and the data available for this exploratory analysis.

DBS, dried blood spot; LCUPA, long chain polyunsaturated fatty acid; ORIP, Omega-3 fats to Reduce the Incidence of Prematurity

Figure 2. Effect of treatment group and time on concentration of DHA and associated oxylipins

DHA, docosahexaenoic acid

Data points are mean fatty acid and oxylin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.0001$.

Figure 3. Effect of treatment group and time on concentration of EPA and associated oxylipins

EPA, eicosapentaenoic acid.

Data points are mean fatty acid and oxylipin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.0001$.

Figure 4. Effect of treatment group and time on concentration of Omega-3

‘Omega-3’, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.

Data points are mean fatty acid and oxylipin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.0001$.

Figure 5. Effect of treatment group and time on concentration of AA and associated oxylipins

AA, Arachidonic acid.

Data points are mean fatty acid and oxylin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.0001$.

Figure 6. Effect of treatment group and time on concentration of LA and associated oxylipins

LA, linoleic acid.

Data points are mean fatty acid and oxylin concentrations by treatment group and time point and error bars are standard errors. Statistical significance of changes over time within treatment groups and differences between treatment groups in the changes over time is indicated by * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.0001$.

Table 1. Baseline Characteristics of women included in the analysis by treatment group

Characteristic	Omega-3 (N=614)	Control (N=649)	Total (n=1263)
Consumed omega-3 containing supplements in the previous 3 mo: n(%)	89 (14.5)	85 (13.1)	174 (13.8)
Maternal age: Median (IQ range)	30.0 (27.0-34.0)	30.0 (27.0-34.0)	30.0 (27.0-34.0)
Gestation: Median (IQ range)*	14.0 (12.6-16.1)	14.1 (12.7-16.4)	14.0 (12.7-16.3)
Mother was primiparous: n/N(%)	280/614 (45.8)	280/648 (43.2)	560/1260 (44.4)
Maternal weight at trial entry: Median (IQ range)**	69.0 (60.0-81.0)	69.0 (60.4-81.4)	69.0 (60.0-81.0)
Maternal white race: n/N(%)	456/614 (74.3)	456/648 (70.4)	912/1262 (72.3)
Mother completed a high-school education: n/N(%)	506/612 (82.7)	499/647 (77.1)	1005/1259 (79.8)
Mother smoked cigarettes at trial entry or leading up to pregnancy: n/N(%)	95/612 (15.5)	101/648 (15.6)	196/1260 (15.6)
Mother drank alcohol at trial entry or leading up to pregnancy: n/N(%)	356/612 (58.2)	362/648 (55.9)	718/1260 (57.0)
Mother had previous preterm delivery: <37 wk of gestation: n/N(%)	37/612 (6.0)	39/648 (6.0)	76/1260 (6.0)
Maternal DHA level (% of total fatty acids): Median (IQ range)	2.7 (2.3-3.1)	2.7 (2.3-3.1)	2.7 (2.3-3.1)
Male fetus: n/N(%)	315/605 (52.1)	317/636 (49.8)	632/1241 (50.9)
Fatty acid status			
- Total DHA: Mean (SD)	2.7 (0.6)	2.8 (0.7)	2.7 (0.6)
- Free DHA: Mean (SD)	0.9 (0.5)	0.9 (0.4)	0.9 (0.5)
- Total EPA: Mean (SD)	0.5 (0.2)	0.5 (0.2)	0.5 (0.2)
- Free EPA: Mean (SD)	0.1 (0.1)	0.1 (0.1)	0.1 (0.1)
- Omega-3 [†] : Mean (SD)	4.9 (0.8)	4.9 (1.0)	4.9 (0.9)
- Free Omega-3 [†] : Mean (SD)	1.1 (0.6)	1.1 (0.5)	1.1 (0.6)
- Total LA: Mean (SD)	19.4 (2.5)	19.3 (2.5)	19.3 (2.5)
- Free LA: Mean (SD)	3.8 (2.5)	3.8 (2.1)	3.8 (2.3)
- Total AA: Mean (SD)	8.2 (1.2)	8.2 (1.2)	8.2 (1.2)
- Free AA: Mean (SD)	1.2 (0.7)	1.2 (0.6)	1.2 (0.6)

* Data were missing for 2 pregnancies in the Omega-3 group.

** Data were missing for 11 pregnancies in the Omega-3 group and 19 in the Control group.

[†]Omega-3 fatty acids, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.

Table 2: Effect of baseline omega-3 status, treatment group and time on concentration of DHA, DHA derived oxylipins and omega-3 fatty acids[†]

Baseline Omega-3[†] Status	Omega-3 Group Baseline Mean (SD)	Control Group Baseline Mean (SD)	Omega-3 Group 34 weeks Mean (SD)	Control Group 34 weeks Mean (SD)	Omega-3 Group Effect*	Control Group Effect*	Difference**	Interaction P-value***
DHA								
≤4.1%	2.03 (0.27)	1.98 (0.31)	2.81 (0.91)	1.96 (0.43)	0.77 (0.56, 0.99)	-0.02 (-0.11, 0.07)	0.80 (0.57, 1.03)	0.19
>4.1 - ≤4.9	2.50 (0.33)	2.52 (0.31)	3.20 (0.91)	2.35 (0.42)	0.71 (0.59, 0.83)	-0.17 (-0.22, -0.11)	0.87 (0.74, 1.01)	
>4.9%	3.21 (0.54)	3.26 (0.61)	3.64 (0.85)	2.67 (0.55)	0.43 (0.31, 0.54)	-0.59 (-0.66, -0.51)	1.01 (0.88, 1.15)	
Free DHA								
≤4.1%	0.84 (0.59)	0.72 (0.32)	0.59 (0.33)	0.39 (0.16)	-0.26 (-0.38, -0.14)	-0.33 (-0.39, -0.27)	0.07 (-0.07, 0.20)	0.06
>4.1 - ≤4.9	0.88 (0.48)	0.88 (0.44)	0.70 (0.40)	0.49 (0.20)	-0.17 (-0.25, -0.10)	-0.39 (-0.45, -0.34)	0.22 (0.13, 0.32)	
>4.9%	0.90 (0.46)	0.94 (0.44)	0.78 (0.40)	0.56 (0.25)	-0.12 (-0.19, -0.05)	-0.38 (-0.44, -0.33)	0.26 (0.17, 0.35)	
4-HDHA								
≤4.1%	20.04 (29.41)	13.33 (11.48)	10.35 (8.48)	7.41 (5.43)	-9.52 (-15.49, -3.54)	-5.93 (-8.19, -3.67)	-3.59 (-9.98, 2.80)	0.06
>4.1 - ≤4.9	18.79 (24.32)	17.88 (18.95)	13.73 (12.60)	9.44 (6.63)	-5.13 (-8.49, -1.77)	-8.47 (-10.95, -5.98)	3.34 (-0.85, 7.52)	
>4.9%	16.59 (14.23)	17.89 (14.31)	14.52 (13.58)	10.76 (8.13)	-1.96 (-4.42, 0.49)	-7.05 (-9.01, -5.09)	5.08 (1.93, 8.23)	
7-HDHA								
≤4.1%	0.96 (1.13)	0.85 (0.64)	0.83 (0.62)	0.59 (0.29)	-0.13 (-0.32, 0.06)	-0.26 (-0.38, -0.15)	0.13 (-0.09, 0.35)	0.02
>4.1 - ≤4.9	1.13 (1.83)	0.97 (0.80)	1.15 (1.04)	0.75 (0.39)	0.01 (-0.25, 0.27)	-0.23 (-0.33, -0.12)	0.24 (-0.04, 0.52)	
>4.9%	0.95 (0.67)	1.05 (0.68)	1.29 (0.97)	0.86 (0.46)	0.33 (0.19, 0.48)	-0.19 (-0.28, -0.09)	0.52 (0.35, 0.69)	
14-HDHA								
≤4.1%	6.18 (8.72)	5.65 (6.79)	5.51 (8.02)	3.16 (3.29)	-0.42 (-2.67, 1.84)	-2.53 (-4.03, -1.02)	2.11 (-0.61, 4.82)	0.27
>4.1 - ≤4.9								

Baseline Omega-3 [†] Status	Omega-3 Group Baseline Mean (SD)	Control Group Baseline Mean (SD)	Omega-3 Group 34 weeks Mean (SD)	Control Group 34 weeks Mean (SD)	Omega-3 Group Effect*	Control Group Effect*	Difference**	Interaction P-value***
>4.9%	7.35 (5.98)	9.38 (10.46)	6.20 (5.39)	4.10 (3.37)	-1.13 (-2.11, -0.14)	-5.23 (-6.47, -4.00)	4.11 (2.53, 5.69)	
19,20EpDPA								
≤4.1%	0.24 (0.30)	0.18 (0.27)	0.31 (0.25)	0.19 (0.18)	0.05 (-0.01, 0.12)	-0.00 (-0.05, 0.05)	0.05 (-0.03, 0.14)	0.14
>4.1 - ≤4.9	0.25 (0.31)	0.26 (0.32)	0.45 (0.35)	0.30 (0.21)	0.18 (0.13, 0.24)	0.02 (-0.02, 0.07)	0.16 (0.09, 0.23)	
>4.9%	0.33 (0.42)	0.32 (0.33)	0.50 (0.39)	0.44 (1.49)	0.15 (0.09, 0.22)	0.11 (-0.09, 0.30)	0.04 (-0.16, 0.25)	
Omega-3[†] fatty acids								
≤4.1%	3.76 (0.34)	3.70 (0.36)	4.49 (1.06)	3.53 (0.85)	0.73 (0.47, 0.99)	-0.17 (-0.35, 0.01)	0.90 (0.59, 1.21)	0.15
>4.1 - ≤4.9	4.52 (0.23)	4.53 (0.22)	5.03 (1.17)	4.09 (0.74)	0.51 (0.35, 0.67)	-0.45 (-0.55, -0.35)	0.96 (0.77, 1.14)	
>4.9%	5.63 (0.70)	5.71 (0.79)	5.59 (1.10)	4.48 (0.74)	-0.04 (-0.20, 0.11)	-1.23 (-1.35, -1.12)	1.19 (0.99, 1.38)	
Free Omega-3[†] fatty acids								
≤4.1%	1.04 (0.73)	0.88 (0.39)	0.72 (0.39)	0.52 (0.21)	-0.31 (-0.46, -0.17)	-0.37 (-0.44, -0.29)	0.05 (-0.11, 0.21)	0.04
>4.1 - ≤4.9	1.08 (0.60)	1.09 (0.54)	0.89 (0.51)	0.63 (0.26)	-0.19 (-0.29, -0.10)	-0.45 (-0.52, -0.38)	0.26 (0.14, 0.38)	
>4.9%	1.10 (0.55)	1.15 (0.52)	0.97 (0.50)	0.73 (0.32)	-0.13 (-0.21, -0.04)	-0.42 (-0.49, -0.36)	0.30 (0.19, 0.40)	

DHA, docosahexaenoic acid;

[†]Omega-3, sum of docosahexaenoic acid, eicosapentaenoic acid, docosapentaenoic acid and alpha linolenic acid.

* Values are estimated difference in the mean fatty acid or oxylipin concentrations (95% confidence interval) for 34 weeks' vs baseline adjusted for enrolment centre and recent omega-3 supplementation by baseline total omega-3 status. Positive values indicate fatty acid or oxylipin concentrations are increasing over time. Negative values indicate fatty acid or oxylipin concentrations are decreasing over time.

** Values are estimated difference in the mean change in fatty acid or oxylipin concentrations over time (95% confidence interval) for omega-3 vs control adjusted for enrolment centre and recent omega-3 supplementation by baseline total omega-3 status.

*** P-value for the 3-way interaction between baseline omega-3 status, treatment group and time. Results should be interpreted with caution where the interaction is not statistically significant.

REFERENCES

1. Middleton P, Gomersall JC, Gould JF, Shepherd E, Olsen SF, Makrides M. Omega-3 fatty acid addition during pregnancy. *Cochrane Database Syst Rev*. 2018;11(11):CD003402.
2. Samuel TM, Sakwinska O, Makinen K, Burdge GC, Godfrey KM, Silva-Zolezzi I. Preterm Birth: A Narrative Review of the Current Evidence on Nutritional and Bioactive Solutions for Risk Reduction. *Nutrients*. 2019;11(8):1811.
3. Yuan ZX, Majchrzak-Hong S, Keyes GS, Iadarola MJ, Mannes AJ, Ramsden CE. Lipidomic profiling of targeted oxylipins with ultra-performance liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem*. 2018;410(23):6009-29.
4. Gabbs M, Leng S, Devassy JG, Monirujjaman M, Aukema HM. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. *Adv Nutr*. 2015;6(5):513-40.
5. Tessaro FH, Ayala TS, Martins JO. Lipid mediators are critical in resolving inflammation: a review of the emerging roles of eicosanoids in diabetes mellitus. *Biomed Res Int*. 2015;2015:568408.
6. Narumiya S, Furuyashiki T. Fever, inflammation, pain and beyond: prostanoid receptor research during these 25 years. *The FASEB Journal*. 2011;25(3):813-8.
7. Corsinovi L, Biasi F, Poli G, Leonarduzzi G, Isaia G. Dietary lipids and their oxidized products in Alzheimer's disease. *J Molecular nutrition food research*. 2011;55(S2):S161-SS72.
8. Amtul Z, Uhrig M, Wang L, Rozmahel RF, Beyreuther K. Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimer's disease: structural insight. *Neurobiol Aging*. 2012;33(4):831 e21-31.
9. Allen KG, Harris MA. The role of n-3 fatty acids in gestation and parturition. *Experimental biology and medicine (Maywood, NJ)*. 2001;226(6):498-506.
10. Keelan JA, Mas E, D'Vaz N, et al. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. 2015;149(2):171-8.
11. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. *Chem Rev*. 2011;111(10):5922-43.
12. Simmonds L.A STR, Skubisz M, Middleton P.F, Best K.P, Yelland L.N, Quinlivan J, Zhou S.J, Liu G, McPhee A.J, Gibson R.A, Makrides M. Omega-3 fatty acid supplementation in pregnancy – baseline omega-

- 3 status and early preterm birth: exploratory analysis of a randomised controlled trial. BJOG: An International Journal of Obstetrics & Gynaecology. 2020.
13. Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047-67.
14. Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851(4):469-84.
15. Buczynski MW, Dumlao DS, Dennis EA. Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res. 2009;50(6):1015-38.
16. Zhou SJ, Best K, Gibson R, et al. Study protocol for a randomised controlled trial evaluating the effect of prenatal omega-3 LCPUFA supplementation to reduce the incidence of preterm birth: the ORIP trial. BMJ Open. 2017;7(9):e018360.
17. Makrides M, Best K, Yelland L, et al. A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery. N Engl J Med. 2019;381(11):1035-45.
18. Liu G, Muhlhausler BS, Gibson RA. A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application. Prostaglandins Leukot Essent Fatty Acids. 2014;91(6):251-60.
19. Hewawasam E, Liu G, Jeffery DW, Muhlhausler BS, Gibson RA. A validated method for analyzing polyunsaturated free fatty acids from dried blood spots using LC-MS/MS. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2017;125:1-7.
20. Hewawasam E, Liu G, Jeffery DW, Muhlhausler BS, Gibson RA. A stable method for routine analysis of oxylipins from dried blood spots using ultra-high performance liquid chromatography-tandem mass spectrometry. J Prostaglandins, Leukotrienes and Essential Fatty Acids. 2018;137:12-8.
21. Ramsden CE, Makrides M, Yuan Z-X, et al. Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth? J Prostaglandins, Leukotrienes and Essential Fatty Acids. 2020;153:102041.
22. Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. J Cochrane Database of Systematic Reviews. 2014(6).

23. Olson DM, Ammann C. Role of the prostaglandins in labour and prostaglandin receptor inhibitors in the prevention of preterm labour. *Front Biosci.* 2007;12(1):1329-43.
24. Makrides M, Neumann MA, Gibson RA. Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition. *Eur J Clin Nutr.* 1996;50(6):352-7.

5544 pregnancies underwent randomization

2770 pregnancies assigned to the
omega-3 LCPUFA group

2774 pregnancies assigned to the
control group

N=1382 pregnancies randomly selected from cohort for dry blood
spot analysis to measure free fatty acids and oxylipins

671 omega-3 LCPUFA group
pregnancies

711 control group pregnancies

57 pregnancies excluded

- 10 *not a singleton pregnancy*
- 47 *no baseline DBS*

62 pregnancies excluded

- 10 *not a singleton pregnancy*
- 52 *no baseline DBS*

614 pregnancies in analysis

649 pregnancies in analysis

Treatment Group ● Control ● Omega-3

Treatment Group ● Control ● Omega-3

Treatment Group —●— Control —●— Omega-3